此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Genitourinary Tumors With Sacituzumab Tirumotecan (RINGQUEST)

RINGQUEST: Exploring Understudied Genitourinary Tumors With Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study

RINGQUEST is a Phase 2, open-label, single arm, basket, investigator-initiated clinical trial of sacituzumab tirumotecan in patients with:

  • Cohort 1: papillary renal carcinoma (pRCC).
  • Cohort 2: less frequent bladder tumors such as variant histology urothelial carcinoma (VH-UC). The most common VH-UC are nested, microcystic, micropapillary, lymphoepithelioma-like, plasmacytoid, giant cell, poorly differentiated, lipid-rich, clear cell, sarcomatoid) bladder cancer and non-urothelial bladder cancer of epithelial origin including squamous cell carcinoma and adenocarcinoma (urachal and non-urachal).

研究概览

详细说明

The study aim to evaluate the efficacy of Sacituzumab Tirumotecan in patients with rare genitourinary tumors: pRCC and VH-UC by means of objective response rate (ORR) according to RECIST 1.1 criteria.

The trial will follow a Simon two-stage design to enroll competitively up to 100 patients, 50 pRCC and 50 VH-UC. The study will enroll the first 15 patients within each cohort 1 and 2, respectively, and monitor for responses. If the interim analysis surpasses the futility threshold (4 or more tumor responses) in any cohort, that cohort will be expanded up to the total expected patients.

All patients will undergo periodic tumor assessments by CT or MRI scan at screening, cycle 4 day 1, cycle 8 day 1, cicle 12 day 1 and every 12 weeks ± 14 days (3 months) thereafter until progression or patient withdrawal. Further CT/MRI scans could be performed upon suspicion of disease progression according to standard clinical practice and physician criteria. Safety safety (AEs, comorbidities) will be assessed at every visit through continuous monitoring of signs and symptoms and periodic laboratory analysis. The study also includes the assessment of patient reported outcomes regarding quality of life (QoL) that will be assessed through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30).

Additionally, Trophoblast cell surface antigen 2 (TROP-2) expression levels and tumor mutations and genetic alterations will be centrally reviewed in tumor biopsies or archival tumor tissue obtained as close as possible to the baseline.

The study includes an exploratory genomic, transcriptomic, and immune-microenvironment characterization analyses that will map responders versus non-responders.

研究类型

介入性

注册 (估计的)

100

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Madrid
      • Madrid、Madrid、西班牙、28041
        • Hospital Universitario 12 de Octubre
        • 接触:
        • 首席研究员:
          • A Principal Investigator designed by the Sponsor, M.D.; Ph.D.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

Informed Consent

  1. The participant provides written informed consent for the study.
  2. Be willing and able to comply with study procedures, laboratory tests, and other requirements of the study.

    Disease Characteristics

  3. Histologically confirmed diagnosis of metastatic or locally advanced unresectable:

    • Cohort 1: papillary renal carcinoma (pRCC).
    • Cohort 2: variant histology urothelial carcinoma (VH-UC) including the following subtypes:

    nested, microcystic, micropapillary, lymphoepithelioma-like, plasmacytoid, giant cell, poorly differentiated, lipid-rich, clear cell, sarcomatoid) bladder cancer and non-urothelial bladder cancer of epithelial origin including squamous cell carcinoma and adenocarcinoma (urachal and non-urachal).

    Note: Variant histology tumors and non-urothelial tumors of ureter, urethra, urachus, or renal pelvis are included.

    Note: Patients with mixed cell type are eligible if the predominant histology (over 50%) is variant or non-urothelial. All histological classifications will follow the 2022 world health organization (WHO) Classifications.

  4. Disease progression after standard treatment or lack of available standard treatment options:

    • Cohort 1: Prior treatment with PD-1/PD-L1 and or tyrosine kinase inhibitors (TKIs)
    • Cohort 2: Disease progression after standard treatment. Some VH such as micropapillary, small cell, and sarcomatoid variants are considered highly aggressive and no standard treatments are clearly defined, being considered an orphan disease, so they might be included in the first line in case of lack of available standard treatment options.
  5. Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.

    Note: Lesions situated in a previously-irradiated area are considered measurable if progression has been shown in such lesions.

    Demographics

  6. Is an individual of any sex/gender and is at least 18 years of age at the time of providing the informed consent.

    Patient Status

  7. Has an eastern cooperative Oncology Group Performance status (ECOG PS) of 0 - 1.
  8. Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (except for alopecia and vitiligo).

    Note: Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible.

  9. Adequate organ function. Specimens must be collected within 10 days before the start of study intervention:

    absolute neutrophil count (ANC) ≥1500/µL * Platelets ≥100,000/µL Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/L * Measured or calculated creatinine clearance (CrCl) ≥30 mL/min Total bilirubin ≤1.5 × upper limit normal (ULN) OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN aspartate aminotransferase (AST, SGOT) and alanine aminotransferase (ALT, SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases) Albumin ≥3.0 g/dL ** international normalized ratio (INR) or prothrombin time (PT) / activated patial thromboplastin (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

    * without colony-stimulating factors, erythropoietin dependency, and without packed red blood cell (pRBC) transfusion within the preceding 2 weeks.

    ** without albumin supplementation within the last 72 hours.

  10. Has provided an archival tumor tissue sample or most recently obtained core, incisional, or excisional biopsy of a tumor lesion from any site (primary or metastasis) not previously irradiated. Sites should follow local guidelines regarding fresh tissue collection. Tissue is required for determination of TROP-2 status by the central laboratory. No central pathological review and TROP-2 expression level assessment will be needed to include the patient in the trial.
  11. HIV-infected participants must have well-controlled HIV on antirretroviral therapy (ART), defined as:

    • Having a CD4+ T-cell count ≥350 cells/mm3 at the time of screening
    • Having achieved and maintained virologic suppression, defined as confirmed HIV RNA level below 50 or the lower limit of quantification using the locally available assay, at the time of screening and for at least 12 weeks before screening
    • Absence of any AIDS-defining opportunistic infections within the past 12 months
    • Being on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before randomization and agreeing to continue ART throughout the study Note: The ART regimen must not contain any antiretroviral medications that are strong CYP3A4 inducers/inhibitors/substrates.
    • HIV testing at screening is not required unless:

    There is a known history of HIV infection Mandated by local guidelines

  12. Participants who are HBsAg positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load before randomization.

    Note: Participants should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.

    - Hepatitis B testing at screening is not required unless: There is a known history of HBV infection Mandated by local guidelines

  13. Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.

    Note: Participants must have completed curative antiviral therapy at least 4 weeks before randomization.

    - Hepatitis C testing at screening is not required unless: There is a known history of HCV infection Mandated by local guidelines

    Male Participants

  14. If capable of producing sperm, the participant agrees to the following during the intervention period and for at least 120 days after the last dose of sacituzumab tirumotecan:

    • Refrains from donating sperm.
    • Uses a penile/external condom when having penile-vaginal intercourse with a nonparticipant of childbearing potential who is not currently pregnant plus partner use of an additional contraceptive method, as a condom may break or leak.

    Note: If the participant is azoospermic (vasectomized or secondary to medical cause, documented from the site personnel's review of the participant's medical records, medical examination, or medical history interview), no contraception is required.

    Female Participants

  15. A participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies:

    • Is not a women of childbearing potential (WOCBP) OR
    • Is a WOCBP and:

Has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

Medical history, menstrual history, and recent sexual activity has been reviewed by the physician investigator to decrease the risk for inclusion of a WOCBP with an early undetected pregnancy.

The participant agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during this period for the purpose of reproduction.

Uses a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) during the intervention period and for at least 210 days after the last dose of sacituzumab tirumotecan.

Note: The physician investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by WOCBPs should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions are more stringent than the requirements above, the local label requirements are to be followed.

Abstains from breastfeeding during the study intervention period and for at least 10 days after study intervention.

Exclusion Criteria:

Medical Conditions

  1. Symptomatic brain metastases or leptomeningeal disease. Note: Participants with previously-treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during study screening, are clinically stable, and have not required steroid treatment for at least 14 days before the first dose of study intervention.
  2. Has an active infection requiring systemic therapy other than those permitted in the inclusion criteria.
  3. Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
  4. Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/interstitial lung disease or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
  5. Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of cardiac QT interval corrected by Fridericia formula (QTcF) to >480 ms, and/or other serious cardiovascular and cerebrovascular diseases within 6 months before the first dose of study intervention.
  6. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.

    Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding carcinoma in situ of the bladder) who have undergone potentially curative resection are not excluded.

    Note: Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.

  7. Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the individual's ability to cooperate with the requirements of the study, or interfere with the individual's participation for the full duration of the study, such that it is not in the best interest of the individual to participate, in the opinion of the treating physician investigator.

    Prior/Concomitant Therapy

  8. Received prior treatment with a TROP-2-targeted antibody drug conjugate (ADC).
  9. Received prior treatment with a topoisomerase 1 inhibitor-containing ADC.
  10. Received prior systemic anticancer therapy within 2 weeks before the first dose of study intervention.
  11. Received prior radiotherapy within 2 weeks before the first dose of study intervention, has radiation-related toxicities, requiring corticosteroids, and/or has had radiation pneumonitis.

    Note: Two weeks or fewer of palliative radiotherapy for non-central nervous system disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.

  12. Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
  13. Is currently receiving a strong inducer/inhibitor of CYP3A4 that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks.

    Prior/Concurrent Clinical Study Experience

  14. Is currently enrolled on another therapeutic clinical trial. Concurrent enrollment on another therapeutic clinical trial or any trial designed to impact the efficacy of anti-cancer therapy is prohibited.
  15. Has received an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.

    Other Exclusions

  16. Severe hypersensitivity (Grades ≥3) to study intervention, any of their excipients, and/or to another biologic therapy.
  17. Has had major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention. Anticipation of the need for major surgery during the course of treatment with study intervention is also exclusionary.

Note: Participants who underwent major surgery must have adequately recovered from toxicity and/or complications from the surgery before starting study intervention.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1: papillary renal carcinoma (pRCC)
Patients with pRCC will be included in this group. All patients are allocated to same intervention (sacituzumab tirumotecan), regardless of the cohort

Sacituzumab tirumotecan will be administered by IV infusion on Days 1 of each 2-week cycle.

There is a maximum duration of exposure for sacituzumab tirumotecan of 78 doses (approximately 3 years). Treatment may be prematurely terminated in case of disease progression, unacceptable toxicity, consent withdrawal, or physician criteria.

实验性的:Cohort 2: variant histology urothelial carcinoma (VH-UC)
Patients with VH-UC will be included in this group. All patients are allocated to same intervention (sacituzumab tirumotecan), regardless of the cohort

Sacituzumab tirumotecan will be administered by IV infusion on Days 1 of each 2-week cycle.

There is a maximum duration of exposure for sacituzumab tirumotecan of 78 doses (approximately 3 years). Treatment may be prematurely terminated in case of disease progression, unacceptable toxicity, consent withdrawal, or physician criteria.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective response rate (ORR)
大体时间:Throughout the study period, up to 2 years
Assessed by the investigator through imaging follow-up (CT scan/MRI) using Response evaluation criteria in solid tumors (RECIST) version 1.1. This will be considered as the percentage of patients with confirmed complete response (CR) or partial response (PR) as their overall best response throughout the study period.
Throughout the study period, up to 2 years

次要结果测量

结果测量
措施说明
大体时间
Duration of response (DoR)
大体时间:Throughout the study period, up to 2 years
Time from the first response (complete response [CR] or partial response [PR]) documentation to the date of the documented progressive disease (PD) as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. DoR will be summarized using Kaplan-Meier method.
Throughout the study period, up to 2 years
Progression-free survival (PFS)
大体时间:Throughout the study period, up to 2 years

Time from first dosing date to the date of confirmed PD according to RECIST 1.1. Patients alive and free of events at the date of the analysis will be censored at their last known tumor assessment. Patients who start a new treatment line without progression will be censored on the date of first dose of the subsequent anticancer treatment.

PFS will be summarized using Kaplan-Meier method.

Throughout the study period, up to 2 years
Overall survival (OS)
大体时间:Throughout the study period, up to 2 years
defined as the time elapsed from the first dose of study treatment until death from any cause. Survival will be assessed by recording patient status at each visit. OS will be summarized using Kaplan-Meier method.
Throughout the study period, up to 2 years
Patient reported health-related quality of life (HRQoL)
大体时间:Throughout the study period, up to 2 years

assessed through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), version 3. This is a standard guide with 30 recommendations designed to assess the health of cancer patients. Different scales are measured, including Global Health and Quality of Life, Functional Aspects, and Symptom Scales. The results for each dimension are linearly transformed to generate scores ranging from 0 to 100.

Here we will report the total score:

The top of the scale (100) represents "The best health you can imagine." The bottom of the scale (0) represents "The worst health you can imagine."

Throughout the study period, up to 2 years
Proportion of adverse events leading to treatment discontinuation
大体时间:Throughout the study period, up to 2 years
Defined as the percentage of patients who experience AEs leading to temporary or permanent treatment discontinuation
Throughout the study period, up to 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Guillermo de Velasco, M.D.; Ph.D.、Hospital Universitario 12 de Octubre

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2029年10月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2026年7月16日

首先提交符合 QC 标准的

2026年7月16日

首次发布 (实际的)

2026年7月21日

研究记录更新

最后更新发布 (实际的)

2026年7月23日

上次提交的符合 QC 标准的更新

2026年7月21日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • SC 2025-01
  • 2026-526048-10-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅